Print

Proteonomix, Inc. (PROT) Announces Its Clinical Trial of UMK-121 in Patients With End Stage Liver Disease Has Been Listed on ClinicalTrials.gov  
10/23/2012 12:20:33 PM

PARAMUS, N.J., Oct. 23, 2012 /PRNewswire/ -- PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that the Company's clinical trial of UMK-121 in patients with End Stage Liver Disease has been listed on ClinicalTrials.gov and provided with an Identifier code of NCT01711073.

The listing on ClinicalTrials.gov under regulation FDAAA 801 provides information for families, patients, clinicians, and researchers regarding the trial and its status. We thank the University of Medicine & Dentistry of New Jersey for providing the IRB, a key factor for registration on ClinicalTrials.gov.

Michael Cohen, President of the Company, stated: "We are continuing to progress with our advances and with our target to initiate the clinical trial of UMK-121 in patients with End Stage Liver Disease." The Company will work together with the University and the principal investigators to initiate the clinical study. "The listing of the trial on ClinicalTrials.gov provides patients and their families the opportunity to review the study and evaluate its progress."

About ClinicalTrials.gov

ClinicalTrials.gov is a Web-based resource that provides patients, their family members, health care professionals, researchers, and the public with easy access to information on publicly and privately supported clinical studies on a wide range of diseases and conditions. The Web site is maintained by the National Library of Medicine (NLM) at the National Institutes of Health (NIH). Information on ClinicalTrials.gov is provided and updated by the sponsor or principal investigator of the clinical study. Studies are generally submitted to the Web site (that is, registered) when they begin, and the information on the site is updated throughout the study. In some cases, results of the study are submitted after the study ends. This Web site and database of clinical studies is commonly referred to as a "registry" and "results database." For more information on ClinicalTrials.gov visit the site.

About Proteonomix, Inc.

Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. The Proteonomix family of companies includes Proteoderm, StromaCel, PRTMI and THOR Biopharma. Proteoderm is a wholly owned subsidiary that has developed an anti-aging line of skin care products. StromaCel develops therapeutic modalities for the treatment of cardiovascular disease and for treatment of patients who have suffered post-myocardial infarction. Proteonomix Regenerative Translational Medicine Institute, Inc. (PRTMI) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Additional information is available at www.proteonomix.com and www.proteoderm.com.

Forward-looking statements:

Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made.

SOURCE Proteonomix, Inc.


//-->